KTTA
Pasithea Therapeutics Corp.
Key Financials
Revenue
$486559
↑ 3130.4%
Operating Income
$-20857295
↓ 46.4%
Net Income
$-20427683
↓ 46.9%
EPS (Diluted)
$-2.91
↑ 77.1%
Gross Profit
$-2213
N/A
Total Liabilities
$5.0M
↑ 291.6%
Total Assets
$60.2M
↑ 275.0%
Shareholders' Equity
$55.2M
↑ 273.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 3 | 4/17/2026 | View on SEC |
| SCHEDULE 13G | 4/8/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| SCHEDULE 13G | 2/27/2026 | View on SEC |
| 8-K | 2/20/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G | 2/17/2026 | View on SEC |
| SCHEDULE 13G | 2/12/2026 | View on SEC |
| S-8 | 1/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KTTA |
| Company Name | Pasithea Therapeutics Corp. |
| CIK | 1841330 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (702) 514-4174 |